Johnson & Johnson is paying $785 million upfront for an option to acquire Sail Biomedicines, a bet worth up to about $2.6 billion on a new way of making CAR-T therapy — inside the patient’s own body.
Announced July 30, 2026, the upfront sum breaks down into a $465 million equity investment and $320 million to advance Sail’s technology and programs. J&J also holds an exclusive option to buy the company outright for a further $2.58 billion, bringing the total potential value to roughly $2.6 billion.
What “in vivo” CAR-T means
Conventional CAR-T therapies are made ex vivo: a patient’s immune cells are removed, engineered in a lab to hunt disease, and infused back — a powerful but costly and time-consuming process. In vivo CAR-T instead coaxes the body into making those disease-hunting cells itself, an approach the field hopes will be simpler, cheaper and more scalable.
Sail’s platform
Sail’s technology combines what it calls “endless RNA” with programmable nanoparticles engineered to reach specific cell types. Its lead program, SAIL-0839, is still in preclinical testing, one of four preclinical programs aimed initially at autoimmune disease. Sail was formed in 2023 from the merger of Senda Biosciences and Laronde, both backed by the biotech incubator Flagship Pioneering.
Why it matters
“Sail’s innovative platform represents an exciting new approach that seeks to harness the power of CAR-T therapy in a simpler, more scalable way,” J&J’s R&D head said. The option structure lets J&J stake an early claim on a promising but unproven platform while deferring the full acquisition until the science advances — a hedging tactic increasingly common in high-risk cell and gene therapy.